RVT-3101: "At the expected phase 3 dose, substantial improvements were observed across all key efficacy metrics with chronic dosing"; Ulcerative colitis (Roivant Sciences) - Jun 29, 2023 - RVT-3101 TUSCANY-2 Chronic Period Data Presentation
P2 data • Inflammatory Bowel Disease • Ulcerative Colitis
|